Goldman Sachs logo displayed on a smartphone with stock market percentages on the background. They recently compiled a research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. OMAR MARQUES/SOPA IMAGES/LIGHTROCKET VIA GETTY IMAGES.
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments.
This significant financial reserve will be crucial as patents for some of the industry’s blockbuster drugs are on the expiration cliff.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.